Schizophrenia Research Forum: Drugs In Clinical Trials

Schizophrenia Research Forum - A Catalyst for Creative Thinking

Home

Profile

Membership/Get Newsletter

For Patients & Families


	Recent Updates

	Current Papers

	Search All Papers

	Search Comments

	Research News

	Conference News

	Current Hypotheses

	Idea Lab

	Online Discussions

	Virtual Conferences

	Interviews


	What We Know

	SchizophreniaGene

	Animal Models

	Drugs in Trials

	Research Tools

	Grants

	Jobs

	Conferences

	Journals

	Community Calendar

	General Information

	Member Directory

	Researcher Profiles

	Institutes and Labs

	Mission

	History

	SRF Team

	Advisory Board

	Support Us

	How to Cite

	Fan (E)Mail



	The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.

Drugs In Clinical Trials

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Drug: GLYX-13

Mode of action: Gly site functional partial agonist; monoclonal antibody derived peptide

Phase: Preclinical

Company: Naurex

Note: Add-on to address cognitive/negative symptoms

Useful Links:

Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, Harris RB, Disterhoft JF. GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology . 2005 Dec 1 ; 49(7):1077-87. Abstract


			May 25, 2013




			SRF News SRF Comments Text Size Reset Text Size Email this page







			See our most recent Schizophrenia Bulletin theme Webinar: Taking Stock of Glutamate in Schizophrenia, held 5 February 2013. Check out our Schizophrenia Bulletin theme Webinar: Neurotropic Infectious Agents and Cognitive Impairment in Schizophrenia, held 13 November 2012.